A Study to Compare Oral Absorption of YM060 Between Orally-disintegrating Tablet (Without Water) and Conventional Tablet

Inclusion Criteria: * healthy assessed by the principal investigator or sub-investigators * non-smoking or stop smoking at least 90 days before the study * body weight: over 50.0kg and less than 80.0kg * body mass index (BMI): over 17.6 and less than 26.4 Exclusion Criteria: * participated in another clinical trial (including a post-marketing clinical study) within 120 days before the study * donated 400mL of whole blood within 90 days, 200mL of whole blood within 30 days or blood components within 14 days before the study * received any drugs within 7 days before the study or going to receive any drugs * deviance from normal range in vital signs (blood pressure, pulse rate, and body temperature) or 12-lead ECG * deviance from normal range in lab-tests * history of drug allergy * history or current diagnosis of stomach, small intestine or large intestine diseases * history or current diagnosis of inflammatory bowel disease (Crohn's disease or colitis ulcerative) * history or current diagnosis of colitis ischemic * history or current diagnosis of hepatic diseases * history or current diagnosis of cardiovascular diseases * history or current diagnosis of respiratory diseases * history or current diagnosis of malignant tumor * received ramosetron tablet